| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Inozyme Pharma, Inc.$4
0 (0%)
Market Cap
258.25 M
EPS
-1.68
P/E Ratio
-
Value Trade
5.83 M
0 %
Week
0 %
1 Month
0 %
3 Month
0 %
6 Month
0 %
5 Year
-80.77 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.46 M
52 Week Range
null-null
% held by Insiders
32.82 %
% held by Institutions
62.94 %
Enterprise Value
220.11 M
Total Shares
64.56 M
Short %
7.8 %
Float Shares
43.37 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | INZ-701 (ENPP1 Fc fusion protein enzyme replacement therapy) | Phase 1b data readout | Phase 1b | — | – | – | – |
2024-12-31 | INZ-701 (ENPP1 Fc fusion protein enzyme replacement therapy) | Phase 1b data readout | Phase 1b | — | – | – | – |
2024-12-31 | INZ-701 (ENPP1 Fc fusion protein enzyme replacement therapy) | Phase 1b data readout | Phase 1b | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
INZ-701 Fast Track | ENPP1 Deficiency | — | 2025-05-14 | sustained phosphate increases; 15 had no detectable ADAs or low titer responses; highest titer among these 15 patients was 1,280; two of the 17 patients exhibited higher-titer ADA responses (5,120 and 40,960); median ADA titer at Week 13 was 80 Read More | Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights Read More | |
INZ-701 Fast Track | ENPP1 Deficiency | — | 2025-05-14 | sustained phosphate increases; 15 had no detectable ADAs or low titer responses; highest titer among these 15 patients was 1,280; two of the 17 patients exhibited higher-titer ADA responses (5,120 and 40,960); median ADA titer at Week 13 was 80 Read More | Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights Read More | |
INZ-701 Fast Track | ENPP1 Deficiency | — | 2025-05-14 | sustained phosphate increases; 15 had no detectable ADAs or low titer responses; highest titer among these 15 patients was 1,280; two of the 17 patients exhibited higher-titer ADA responses (5,120 and 40,960); median ADA titer at Week 13 was 80 Read More | Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INZY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INZY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How INZY ranks across every disease it competes inCompetitive Position is a premium feature
See how INZY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial